Posted by Michael Wonder on 09 Mar 2026
Precision BioSciences receives FDA fast track sesignation for PBGENE-DMD
9 March 2026 - Precision BioSciences today announced that the US FDA has granted fast track designation to PBGENE-DMD for the treatment of Duchenne muscular dystrophy.
PBGENE-DMD, a novel first in class gene editing therapy, utilises a gene excision approach that is clearly differentiated from existing microdystrophin and exon skipping treatments.
